CA3020375A1 - Modified bacteriophage - Google Patents

Modified bacteriophage Download PDF

Info

Publication number
CA3020375A1
CA3020375A1 CA3020375A CA3020375A CA3020375A1 CA 3020375 A1 CA3020375 A1 CA 3020375A1 CA 3020375 A CA3020375 A CA 3020375A CA 3020375 A CA3020375 A CA 3020375A CA 3020375 A1 CA3020375 A1 CA 3020375A1
Authority
CA
Canada
Prior art keywords
bacteriophage
modified
phi33
phage
modified bacteriophage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3020375A
Other languages
English (en)
French (fr)
Inventor
Heather Fairhead
Adam Wilkinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phico Therapeutics Ltd
Original Assignee
Phico Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phico Therapeutics Ltd filed Critical Phico Therapeutics Ltd
Publication of CA3020375A1 publication Critical patent/CA3020375A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00031—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2795/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2795/00045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10131—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Lubricants (AREA)
  • Peptides Or Proteins (AREA)
CA3020375A 2016-04-08 2017-04-07 Modified bacteriophage Pending CA3020375A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201606319 2016-04-08
GB1606319.0 2016-04-08
PCT/EP2017/058470 WO2017174810A1 (en) 2016-04-08 2017-04-07 Modified bacteriophage

Publications (1)

Publication Number Publication Date
CA3020375A1 true CA3020375A1 (en) 2017-10-12

Family

ID=58692459

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3020375A Pending CA3020375A1 (en) 2016-04-08 2017-04-07 Modified bacteriophage

Country Status (14)

Country Link
US (2) US11732243B2 (enExample)
EP (2) EP3901255A1 (enExample)
JP (2) JP7051809B2 (enExample)
AU (2) AU2017246593C1 (enExample)
CA (1) CA3020375A1 (enExample)
DK (1) DK3440200T3 (enExample)
ES (1) ES2867029T3 (enExample)
HR (1) HRP20210614T1 (enExample)
HU (1) HUE054475T2 (enExample)
LT (1) LT3440200T (enExample)
PL (1) PL3440200T3 (enExample)
PT (1) PT3440200T (enExample)
SI (1) SI3440200T1 (enExample)
WO (1) WO2017174810A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4727565A1 (en) * 2023-06-13 2026-04-22 Virginia Tech Intellectual Properties, Inc. Engineered phages and uses thereof
WO2025143108A1 (ja) 2023-12-27 2025-07-03 株式会社Arrowsmith 緑膿菌バクテリオファージ

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1246150A (zh) 1997-01-31 2000-03-01 科斯米克斯分子生物有限公司 组合文库的多样性的产生
US6310191B1 (en) 1998-02-02 2001-10-30 Cosmix Molecular Biologicals Gmbh Generation of diversity in combinatorial libraries
US6492161B1 (en) * 1999-06-02 2002-12-10 Prokaria Ltd. Bacteriophage RM 378 of a thermophilic host organism
WO2002007742A2 (en) 2000-07-25 2002-01-31 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bacteriophage having multiple host range
GB0028130D0 (en) 2000-11-17 2001-01-03 Phico Therapeutics Ltd Polypeptide and uses thereof
EP1384779A1 (en) 2002-07-26 2004-01-28 Cosmix Molecular Biologicals GmbH Method for generating molecules with specific properties by recombination and selection
GB0314469D0 (en) * 2003-06-20 2003-07-23 Phico Therapeutics Ltd Antimicrobial compositions and uses thereof
CA2533352C (en) * 2003-07-23 2016-01-19 Biocontrol Limited Bacteriophage-containing therapeutic agents
GB0715416D0 (en) 2007-08-07 2007-09-19 Phico Therapeutics Ltd Modified bacteriophage
DE102010013834A1 (de) 2008-03-30 2010-12-16 VLB Berlin e. V. Institut für Mikrobiologie Mittel zur Blockierung der Vermehrung und der Abtötung von Bakterien
WO2010141135A2 (en) 2009-03-05 2010-12-09 Trustees Of Boston University Bacteriophages expressing antimicrobial peptides and uses thereof
US9617522B2 (en) * 2013-09-05 2017-04-11 Massachusetts Institute Of Technology Tuning bacteriophage host range
GB201417805D0 (en) * 2014-10-08 2014-11-19 Phico Therapeutics Ltd Modifield bacteriophage
GB201417811D0 (en) 2014-10-08 2014-11-19 Phico Therapeutics Ltd Modifying bacteriophage
GB201417808D0 (en) * 2014-10-08 2014-11-19 Phico Therapeutics Ltd Modified bacteriophage
GB201417810D0 (en) * 2014-10-08 2014-11-19 Phico Therapeutics Ltd Modifying bacteriophage

Also Published As

Publication number Publication date
PT3440200T (pt) 2021-04-30
JP2022084893A (ja) 2022-06-07
US20190119651A1 (en) 2019-04-25
EP3440200A1 (en) 2019-02-13
ES2867029T3 (es) 2021-10-20
AU2017246593A1 (en) 2018-11-15
JP2019510519A (ja) 2019-04-18
AU2017246593B2 (en) 2023-04-13
DK3440200T3 (da) 2021-04-26
PL3440200T3 (pl) 2021-08-02
EP3440200B1 (en) 2021-02-24
HRP20210614T1 (hr) 2021-06-11
US11732243B2 (en) 2023-08-22
US20230416694A1 (en) 2023-12-28
HUE054475T2 (hu) 2021-09-28
AU2017246593A2 (en) 2023-04-13
LT3440200T (lt) 2021-05-25
SI3440200T1 (sl) 2021-11-30
JP7051809B2 (ja) 2022-04-11
EP3901255A1 (en) 2021-10-27
AU2023204409A1 (en) 2023-08-03
WO2017174810A1 (en) 2017-10-12
AU2017246593C1 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
US20230265395A1 (en) Multiple host range bacteriophage with hybrid tail fibres
US11236306B2 (en) Multiple host range bacteriophage with different tail fibres
AU2015329959B2 (en) Modifying bacteriophage
US20230416694A1 (en) Modified bacteriophage

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220307